CO6571849A2 - Terapia de combinación que usa un agente o agentes anti-egfr e inhibidores específicos de igf-1r - Google Patents
Terapia de combinación que usa un agente o agentes anti-egfr e inhibidores específicos de igf-1rInfo
- Publication number
- CO6571849A2 CO6571849A2 CO11154175A CO11154175A CO6571849A2 CO 6571849 A2 CO6571849 A2 CO 6571849A2 CO 11154175 A CO11154175 A CO 11154175A CO 11154175 A CO11154175 A CO 11154175A CO 6571849 A2 CO6571849 A2 CO 6571849A2
- Authority
- CO
- Colombia
- Prior art keywords
- inhibitors
- igf
- agents
- combination therapy
- egfr agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se describe la combinación de un antagonista de IGF-1R tal como un anticuerpo humanizado y un fármaco anti-proliferativo. En una realización preferida, la presente invención describe la combinación de un anticuerpo frente a IGF-1R y un fármaco anti-proliferativo que pertenece a la clase de inhibidor de EGFR, que es preferiblemente erlotinib. La combinación de acuerdo con la presente invención es útil para el tratamiento de tumores, que incluyen tumores mediados o dependientes de IGF-1R y/o EGFR.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16976809P | 2009-04-16 | 2009-04-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6571849A2 true CO6571849A2 (es) | 2012-11-30 |
Family
ID=42982796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO11154175A CO6571849A2 (es) | 2009-04-16 | 2011-11-11 | Terapia de combinación que usa un agente o agentes anti-egfr e inhibidores específicos de igf-1r |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20120058112A1 (es) |
| EP (1) | EP2419135A4 (es) |
| JP (1) | JP2012524087A (es) |
| KR (1) | KR20110140126A (es) |
| CN (1) | CN102458466A (es) |
| AU (1) | AU2010236818B2 (es) |
| BR (1) | BRPI1015216A2 (es) |
| CA (1) | CA2757730A1 (es) |
| CL (1) | CL2011002569A1 (es) |
| CO (1) | CO6571849A2 (es) |
| EC (1) | ECSP11011405A (es) |
| IL (1) | IL215363A0 (es) |
| MX (1) | MX2011010911A (es) |
| NZ (1) | NZ595755A (es) |
| RU (1) | RU2011146339A (es) |
| SG (1) | SG175208A1 (es) |
| WO (1) | WO2010120592A1 (es) |
| ZA (1) | ZA201107204B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY32317A (es) | 2008-12-12 | 2010-07-30 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
| US8470297B1 (en) * | 2009-09-10 | 2013-06-25 | Merck Sharp & Dohme Corp. | FDG-pet evaluation of Ewing's sarcoma sensitivity |
| US20140255413A1 (en) | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
| GB201409488D0 (en) * | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| CN105998033B (zh) * | 2016-07-05 | 2018-11-27 | 福州大学 | 一种含有厄洛替尼和熊果酸的药物组合物及其在制备抗肿瘤药物中的应用 |
| CN105963305B (zh) * | 2016-07-05 | 2018-08-17 | 福州大学 | 一种含酪氨酸激酶抑制剂的药物组合物及其在制备抗肿瘤转移药物中的应用 |
| AR127556A1 (es) * | 2021-11-02 | 2024-02-07 | Fusion Pharmaceuticals Inc | Métodos para tratar el cáncer utilizando un radioinmunoconjugado |
| WO2023235822A1 (en) * | 2022-06-03 | 2023-12-07 | Foundation Medicine, Inc. | Igf1r activation mutations and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007012896A (es) * | 2005-04-15 | 2007-12-10 | Schering Corp | Metodos y composiciones para tratamiento o prevencion de cancer. |
| US20090203718A1 (en) * | 2006-04-13 | 2009-08-13 | Smithkline Beecham (Cork) Ltd. | Cancer treatment method |
| EP2236139A1 (en) * | 2009-03-31 | 2010-10-06 | F. Hoffmann-La Roche AG | Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor |
-
2010
- 2010-04-06 RU RU2011146339/15A patent/RU2011146339A/ru not_active Application Discontinuation
- 2010-04-06 CN CN2010800269747A patent/CN102458466A/zh active Pending
- 2010-04-06 BR BRPI1015216A patent/BRPI1015216A2/pt not_active IP Right Cessation
- 2010-04-06 WO PCT/US2010/030022 patent/WO2010120592A1/en active Application Filing
- 2010-04-06 JP JP2012506067A patent/JP2012524087A/ja active Pending
- 2010-04-06 CA CA2757730A patent/CA2757730A1/en not_active Abandoned
- 2010-04-06 SG SG2011074721A patent/SG175208A1/en unknown
- 2010-04-06 KR KR1020117024147A patent/KR20110140126A/ko not_active Application Discontinuation
- 2010-04-06 AU AU2010236818A patent/AU2010236818B2/en not_active Ceased
- 2010-04-06 EP EP10764915A patent/EP2419135A4/en not_active Withdrawn
- 2010-04-06 MX MX2011010911A patent/MX2011010911A/es unknown
- 2010-04-06 NZ NZ595755A patent/NZ595755A/xx not_active IP Right Cessation
- 2010-04-06 US US13/264,595 patent/US20120058112A1/en not_active Abandoned
-
2011
- 2011-09-25 IL IL215363A patent/IL215363A0/en unknown
- 2011-10-03 ZA ZA2011/07204A patent/ZA201107204B/en unknown
- 2011-10-14 CL CL2011002569A patent/CL2011002569A1/es unknown
- 2011-10-17 EC EC2011011405A patent/ECSP11011405A/es unknown
- 2011-11-11 CO CO11154175A patent/CO6571849A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010236818B2 (en) | 2014-03-13 |
| AU2010236818A1 (en) | 2011-11-03 |
| ZA201107204B (en) | 2015-07-29 |
| JP2012524087A (ja) | 2012-10-11 |
| RU2011146339A (ru) | 2013-05-27 |
| NZ595755A (en) | 2013-07-26 |
| BRPI1015216A2 (pt) | 2016-04-12 |
| EP2419135A4 (en) | 2012-11-28 |
| MX2011010911A (es) | 2011-11-02 |
| CL2011002569A1 (es) | 2012-04-09 |
| EP2419135A1 (en) | 2012-02-22 |
| CA2757730A1 (en) | 2010-10-21 |
| ECSP11011405A (es) | 2011-11-30 |
| IL215363A0 (en) | 2011-12-29 |
| US20120058112A1 (en) | 2012-03-08 |
| CN102458466A (zh) | 2012-05-16 |
| SG175208A1 (en) | 2011-11-28 |
| WO2010120592A1 (en) | 2010-10-21 |
| KR20110140126A (ko) | 2011-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6571849A2 (es) | Terapia de combinación que usa un agente o agentes anti-egfr e inhibidores específicos de igf-1r | |
| CY1123470T1 (el) | Αναστολεις ιβατ για την αγωγη ηπατοπαθειων | |
| BR112014024017A8 (pt) | Métodos de tratamento de um tipo de câncer, de tratamento do carcinoma, para selecionar uma terapia e para quantificação e inibidor de her3 | |
| CL2018000223A1 (es) | Combinación de antagonista de pd-1 con un inhibidor de egfr | |
| PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| CL2015002369A1 (es) | Uso de linagliptina en terapia antidiabética cardio y renoprotectora | |
| ECSP14013223A (es) | Métodos para tratar el cáncer por el uso de antagonistas de unión al eje pd-1 e inhibidores de mek | |
| CL2017000285A1 (es) | Terapia combinada para el tratamiento de un paramixovirus | |
| EA201690980A1 (ru) | Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака | |
| UY33498A (es) | Combinaciones de inhibidores de quinasas para el tratamiento de cancer | |
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| CL2015000699A1 (es) | Métodos para tratamiento de cáncer. | |
| GT201300320A (es) | Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cáncer. | |
| ECSP13012394A (es) | Nuevas formas de dosificación de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa | |
| CR20120638A (es) | Métodos de terapia combinada para tratar enfermedades proliferativas | |
| BR112014012607A2 (pt) | métodos de tratamento usando um inibidor de interferon gama | |
| AR056801A1 (es) | Terapia combinada anti- proliferativa con determinados agentes quimioterapeuticos basados en platino e inhibidores de egfr o analogos de pirimidina | |
| CY1120751T1 (el) | Αναστολεις ετεροδικυκλοαρυλιου του rorc2 και μεθοδοι χρησης αυτων | |
| CL2016000379A1 (es) | Composiciones y métodos terapéuticos para reducción acelerada de plagas | |
| CL2015003343A1 (es) | Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico. | |
| BR112014012495A2 (pt) | método in vitro, kit, inibidor de egfr e método de tratamento de pacientes afetados com câncer | |
| CY1120877T1 (el) | Συνθεσεις και μεθοδοι για την αντιμετωπιση της κοιλιοκακης | |
| BR112013017953A2 (pt) | Composição farmacêutica, formulação tópica, método, e, composição fotossensibilizadora | |
| DOP2013000131A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek | |
| EA201590744A1 (ru) | Лечение рака tor киназными ингибиторами |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |